Positive clinical trial results with brelovitug meeting primary endpoints, strong efficacy data (56% and 45% response rates), good safety profile, and clear regulatory pathway with BLA submission expected in H1 2027 and potential commercial launch in Q4 2027.
Articles that tag MIRM but are mainly about other companies.
Mirum is mentioned only as the current employer of the newly appointed board member. The article provides no information about Mirum's business performance or strategic direction, warranting a neutral sentiment.
Listed as a top holding (10.4% of AUM, $33.27M) in the fund's portfolio, representing a significant established position.
Volixibat Phase 2b VISTAS study in PSC expected to report topline data in Q2 2026 and Phase 3 VANTAGE study in PBC expected to complete enrollment in H2 2026, representing upcoming catalysts with uncertain outcomes.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
